Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Eledon Pharmaceuticals, Inc. (ELDN) had Return on Tangible Equity of -33.35% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-45.62M |
|
-- |
|
-- |
|
$83.25M |
|
$-83.25M |
|
$37.67M |
|
$-45.58M |
|
$-45.58M |
|
$-45.62M |
|
$-45.62M |
|
$-45.62M |
|
$-45.62M |
|
$-83.25M |
|
$-83.25M |
|
81.84M |
|
81.84M |
|
$-0.52 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$135.69M |
|
-- |
|
$33.32M |
|
$169.01M |
|
$18.34M |
|
-- |
|
$13.89M |
|
$32.23M |
|
$81.08M |
|
$136.78M |
|
$136.78M |
|
75.43M |
|
| Cash Flow Statement Financials | |
$-62.34M |
|
$10.79M |
|
$53.81M |
|
$20.55M |
|
$22.81M |
|
$2.26M |
|
$10.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.40 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-62.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-56.26% |
|
|
Return on Tangible Equity |
-33.35% |
-26.99% |
|
-33.35% |
|
$1.81 |
|
$-0.76 |
|
$-0.76 |
|